MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7200
-0.0253 (-3.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.7453
Open0.7365
Bid0.7000 x 900
Ask0.7450 x 1800
Day's Range0.7000 - 0.7698
52 Week Range0.3450 - 1.5000
Volume537,846
Avg. Volume766,493
Market Cap102.954M
Beta (3Y Monthly)2.67
PE Ratio (TTM)N/A
EPS (TTM)-0.1450
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)?
    Simply Wall St.12 days ago

    What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)?

    If you want to know who really controls Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB), then you'll have to look at...

  • GlobeNewswire2 months ago

    Matinas BioPharma to Present at the 9th Annual LD Micro Invitational

    Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MTNB earnings conference call or presentation 14-May-19 12:30pm GMT

    Q1 2019 Matinas BioPharma Holdings Inc Earnings Call

  • GlobeNewswire2 months ago

    Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio

    – Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – –.

  • Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GlobeNewswire2 months ago

    Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, has been selected for two presentations at the ASM Microbe 2019 scientific meeting being held June 20–24 in San Francisco, CA.

  • GlobeNewswire2 months ago

    Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

    Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.

  • GlobeNewswire2 months ago

    Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results

    BEDMINSTER, N.J., May 14, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the.

  • GlobeNewswire2 months ago

    Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss operational and financial results for the quarter ended March 31, 2019 as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

  • GlobeNewswire3 months ago

    Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019

    BEDMINSTER, N.J., May 02, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to.

  • GlobeNewswire3 months ago

    Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview and host one-on-one meetings with leading industry executives at BioNJ’s Ninth Annual BioPartnering Conference on Wednesday, May 8, 2019 during the afternoon session being held 2:00 PM – 3:00 PM ET. As part of her presentation, Dr. Matkovits will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform. Matinas’ LNC platform technology offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies.  Dr. Matkovits will also provide an overview of the Company’s lead anti-infective pipeline candidate, MAT2203.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMT

    Full Year 2018 Matinas BioPharma Holdings Inc Earnings Call

  • GlobeNewswire4 months ago

    Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update

    –  Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only.

  • GlobeNewswire4 months ago

    Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019

    The call will be led by Jerome D. Jabbour, Chief Executive Officer of Matinas. Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions.

  • Business Wire4 months ago

    Matinas BioPharma to Present at the 31st Annual ROTH Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • Business Wire4 months ago

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,090,909 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • Business Wire4 months ago

    Matinas BioPharma Announces Proposed Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • GlobeNewswire5 months ago

    Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer.

  • ACCESSWIRE6 months ago

    Biotech Breaking Out

    HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a ...

  • GlobeNewswire6 months ago

    Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology. Formulations will be developed using Matinas’ LNC delivery technology which enables the development of a wide range of difficult-to-deliver molecules. For competitive reasons, the agreement stipulates certain confidential provisions, including the pharmaceutical company’s identity, the therapeutic molecule(s), the intended targets and the financial terms of the agreement.

  • GlobeNewswire7 months ago

    Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed Keith A. Kucinski, CPA, MBA as Chief Financial Officer. Mr. Kucinski brings to Matinas over 20 years of diversified and broad finance expertise with demonstrated leadership and success in financial and strategic planning, accessing the capital markets and mergers and acquisitions across the healthcare and business consulting industries. Jerome D. Jabbour, Chief Executive Officer, commented, “As we look to drive our Company forward in 2019 and maximize the value of our products and platform technology, we have taken deliberate steps to bolster our management team over the past few months.

  • GlobeNewswire7 months ago

    Matinas BioPharma to Present at Biotech Showcase 2019

    As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), a highly potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. The Company recently announced the formation of a Scientific Advisory Board to guide clinical development strategy of its potential best-in-class prescription-only omega-3, MAT9001, and appointed three internationally renowned experts as its first members. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • GlobeNewswire7 months ago

    Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced the appointment of Harold E. Bays, M.D. to its Scientific Advisory Board (SAB). Dr. Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine. Dr. Bays joins the Company’s recently appointed SAB members, Christie M. Ballantyne, M.D., John J.P. Kastelein, M.D., Ph.D., FESC, and Kevin C. Maki, Ph.D., now representing four of the world’s leading lipid specialists and cardiovascular health experts.

  • GlobeNewswire7 months ago

    Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001

    BEDMINSTER, N.J., Dec. 06, 2018 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has established   a.

  • GlobeNewswire8 months ago

    Detailed Research: Economic Perspectives on Sunstone Hotel Investors, Acadia Realty Trust, Matinas Biopharma, Compass Diversified, Aspen Insurance, and Superior Drilling Products — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.